---

---

---

---

•	Increasing worldwide population.

•	Aging population in developed countries requires more dental care and is well positioned to pay for the required procedures since it controls sizable amounts of discretionary income.

•	Natural teeth are being retained longer - Individuals with natural teeth are much more likely to visit a dentist in a given year than those without any natural teeth remaining.

•	Earlier preventive care and a growing demand for aesthetic dentistry - Dentistry has evolved from a profession primarily dealing with pain, infections and tooth decay to one with increased emphasis on preventive care and cosmetic dentistry.

•	Increasing demands for patient comfort and ease of product use and handling.

•	Increasing demand for more efficiency and better workflow in the dental office, including digital and integrated solutions.

•	Per capita and discretionary incomes are increasing in emerging markets. As personal incomes continue to rise in emerging economies, healthcare, including dental services, is a growing priority. Many surveys indicate the middle class population will expand significantly within these emerging markets.

•

The Company’s business is less susceptible than many other industries to general downturns in the economies in which it operates. Many of the products the Company offers relate to dental procedures and health conditions that are considered necessary by patients regardless of the economic environment. Dental specialty products, dental equipment and products that support discretionary dental procedures are the most susceptible to changes in economic conditions.

---

---

---

---

---

---

•	the inability to successfully combine DENTSPLY and Sirona’s businesses in a manner that permits Dentsply Sirona to achieve the full revenue and cost synergies anticipated to result from the Merger;

•	complexities associated with managing the combined businesses, including the challenge of integrating complex systems, technology, networks and other assets of each of the companies in a seamless manner that minimizes any adverse impact on customers, suppliers, employees and other constituencies;

•	coordinating geographically separated organizations, systems and facilities;

•	addressing possible differences in business backgrounds, corporate cultures and management philosophies;

•	integrating the workforces of the two companies while maintaining focus on providing consistent, high quality customer service;

•	potential unknown liabilities and unforeseen increased or new expenses, delays or regulatory conditions associated with the Merger;

•	Dentsply Sirona’s current and prospective employees may experience uncertainty about their roles within Dentsply Sirona following the Merger, which may have an adverse effect on the ability of Dentsply Sirona to attract or retain key management and other key personnel; and

•	No assurance can be given that Dentsply Sirona will be able to attract or retain key management personnel and other key employees to the same extent that DENTSPLY and Sirona have previously been able to attract or retain employees, which could have a negative impact on their respective businesses.

•	diversion of the attention of Dentsply Sirona’s management;

•	disruption of existing relationships with distributors, suppliers and other manufacturers in the industry that drive a substantial amount of revenues to Dentsply Sirona; and

•

the disruption of, or the loss of momentum in, Dentsply Sirona’s ongoing businesses or inconsistencies in standards, controls, procedures and policies, any of which could adversely affect Dentsply Sirona’s ability to maintain relationships with customers, suppliers, employees and other constituencies, Dentsply Sirona’s ability to achieve the anticipated benefits of the Merger, or which could reduce Dentsply Sirona’s earnings or otherwise adversely affect the business and financial results of Dentsply Sirona.

---

---

---

•	the timing of new product introductions by Dentsply Sirona and its competitors;

•	timing of industry trade shows;

•	changes in customer inventory levels;

•	developments in government reimbursement policies;

•	changes in customer preferences and product mix;

•	the Company’s ability to supply products to meet customer demand;

•	fluctuations in manufacturing costs;

•	changes in income tax laws and incentives which could create adverse tax consequences;

•	fluctuations in currency exchange rates; and

•	general economic conditions, as well as those specific to the healthcare and related industries.

---

---

---

---

---

---

---

•	the pending patent applications that Dentsply Sirona has filed, or to which Dentsply Sirona has exclusive rights, may not result in issued patents or may take longer than Dentsply Sirona expects to result in issued patents;

•	the allowed claims of any patents that are issued may not provide meaningful protection;

•	Dentsply Sirona may be unable to develop additional proprietary technologies that are patentable;

•	the patents licensed or issued to Dentsply Sirona may not provide a competitive advantage;

•	other companies may challenge patents licensed or issued to Dentsply Sirona;

•	disputes may arise regarding inventions and corresponding ownership rights in inventions and know-how resulting from the joint creation or use of intellectual property by Dentsply Sirona and Dentsply Sirona’s respective licensors; and

•	other companies may design around the technologies patented by Dentsply Sirona.

---

•	assert against others or defend Dentsply Sirona against claims of infringement;

•	enforce patents owned by, or licensed to Dentsply Sirona from, another party;

•	protect Dentsply Sirona’s trade secrets or know-how; or

•	determine the enforceability, scope and validity of Dentsply Sirona’s proprietary rights or the proprietary rights of others.

•	Economic and political instability;

•	Import or export licensing requirements;

•	Additional compliance-related risks;

•	Trade restrictions and tariffs;

•	Product registration requirements;

•	Longer payment cycles;

•	Changes in regulatory requirements and tariffs;

•	Fluctuations in currency exchange rates;

•	Potentially adverse tax consequences; and

•	Potentially weak protection of intellectual property rights.

---

•	making it more difficult for the Company to satisfy its obligations with respect to its indebtedness;

•	requiring Dentsply Sirona to dedicate significant cash flow from operations to the payment of principal and interest on its indebtedness, which would reduce the funds the Company has available for other purposes, including working capital, capital expenditures and acquisitions; and

•	reducing Dentsply Sirona’s flexibility in planning for or reacting to changes in its business and market conditions.

---

---

---

(1)	These properties are included in the Dental and Healthcare Consumables segment.

---

(2)	These properties are included in the Technologies segment.

(3)	This property is a distribution warehouse not managed by named segments.

---

---

---

---

---

•	Business - a general description of Dentsply Sirona’s business and how performance is measured;

•	Results of Operations - an analysis of the Company’s consolidated results of operations for the three years presented in the Consolidated Financial Statements;

•	Critical Accounting Estimates - a discussion of accounting policies that require critical judgments and estimates; and

•	Liquidity and Capital Resources - an analysis of cash flows; debt and other obligations; and aggregate contractual obligations.

•

The Company closed its merger between DENTSPLY International Inc. and Sirona Dental Systems, Inc. on February 29, 2016 and established Dentsply Sirona as The Dental Solutions Company™ and the largest manufacturer of dental products for the professional dental market. The Company is best positioned to foster the development of differentiated integrated solutions for general practitioners and specialists.

•

For the year ended December 31, 2016, net sales, excluding precious metal content, increased 42.6% compared to prior year. The increase in sales primarily reflects the impact of consolidating ten months of Sirona’s sales. For the year ended December 31, 2016, sales of our combined businesses (a non-US GAAP measure as referenced above), grew 3.6% on a constant currency basis. This includes a benefit of 1.7% from net acquisitions and was unfavorably impacted by discontinued products by approximately 50 basis points, which results in internal growth of 2.4%.

•

For the year ended December 31, 2016, net income attributable to Dentsply Sirona increased 71.2%. Earnings per diluted share of $1.94 increased by 10.2% from $1.76 in the prior year. On an adjusted basis (a non-US GAAP measure as defined under the heading “Net Income attributable to Dentsply Sirona” ), full year 2016 net income grew 64.7% and earnings per diluted share grew 5.7% to $2.78 from $2.62 in the prior year. The Company’s results reflect a significant earnings headwind from currency rate changes compared to the prior year of approximately 3.0%, or $0.08 per diluted share.

•

In 2016, the Company initiated merger and integration activities to capture cost and revenue synergies. The Company completed the elimination of certain corporate redundancies, the planning of country consolidation activities and the renegotiating of supply contracts with vendors. Additionally, the Company initiated reorganization activities that include manufacturing and logistics. The Company achieved tax savings as it realized complementary tax attributes of the combined businesses. With regard to revenue synergies, Dentsply Sirona launched combined commercial activities, such as bundling products and developing cross-selling opportunities. Investments in research and development have yielded new products and solutions which is expected to generate sales growth in the future.

---

•

During 2016, the Company deployed cash in excess of $1.2 billion as it returned cash to shareholders through common share repurchases and dividend payments, as well as strengthened the business through acquisitions. During 2016, the Company completed two acquisitions with an aggregate purchase price of $341.1 million, including the acquisition of MIS Implants Technologies Ltd. (“MIS”), a manufacturer of dental implant systems, and a small acquisition of a healthcare consumable business. In addition, the Company repurchased $813.9 million of common shares outstanding in 2016.

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

(1)	ARTICLE I, Sections 1 (Annual Meetings) and 2 (Special Meetings) were revised to provide that the Company may postpone, reschedule or cancel any annual or special meeting previously called by the Board of Directors.

(2)	ARTICLE I, Section 3 (Place of Meeting) was revised by deleting that a waiver of notice signed by all stockholders entitled to vote at a meeting may designate any place as the place for such meeting.

(3)	ARTICLE I, Section 4 (Notice of Meeting) was revised (i) to provide for the possibility of meeting attendance via remote communication and different record dates for notice and voting rights; and (ii) by deleting that notice may be delivered personally or by mail at the discretion of the Chief Executive Officer or the officer or persons calling the meeting.

(4)	ARTICLE I, Section 5 (Fixing of Record Date) was revised (i) to provide for the possibility of different record dates for notice and voting rights as well as certain stipulation with regards to the fixing of record dates; and (ii) by deleting that the stock transfer books may not be closed before the record date for notice, voting or dividend rights.

(5)	ARTICLE I, Section 6 (Quorum; Adjournments) was revised (i) to provide further detail regarding the adjournment and reconvening of meetings, and (ii) by deleting a provision by which a meeting is property constituted if notice was properly given, waived or deemed waived.

(6)	ARTICLE I, Section 7 (Proxies) was revised to provide that proxies shall be valid for up to three years from their date of issuance and may only be irrevocable if coupled with an interest sufficient in law to support an irrevocable power.

(7)	ARTICLE I, Section 8 (Voting of Shares) was revised (i) to provide for the possibility of different record dates for notice and voting rights; and (ii) by deleting that shares of a corporation may be voted by any officer or proxy appointed by any officer in the absence of express notice that such officer has no authority to vote.

(8)	ARTICLE I, Section 9 (List of Stockholders) was revised to provide certain details with regards to the preparation and examination of the stock ledger, as well as providing for the possibility of access via an electronic network and meetings held solely by means of remote communication.

(9)	ARTICLE I, Section 10 (Waiver of Notice by Stockholders) was revised to provide for the possibility of electronic transmission of a waiver.

(10)

ARTICLE I, Sections 11 (Advance Notice) and 12 (Procedure for Nomination of Directors) were revised to provide that where the annual meeting is called for a date that is more than 30 days before or 60 days after its anniversary date, notice is timely if received not later than the close of business on the 90th day prior to the annual meeting or, if later, the 10th day following mailing of the notice or public disclosure of the annual meeting.

(11)	ARTICLE I, Section 13 (Stockholder Voting) was revised to provide that all other proposals aside from director elections shall be decided by a majority vote of the shares present in person or by proxy and entitled to vote, unless otherwise required by applicable laws, rules or regulations, the Company’s Certificate of Incorporation or By-laws.

(12)	ARTICLE I, Section 14 (Conduct of Meetings) was inserted to provide certain procedural guidelines for the conduct of meetings and stipulate certain powers of the presiding person.

(13)	ARTICLE II, Section 1 (General Powers) was revised to provide that the business and affairs of the Company may be managed under the direction of the Board of Directors.

---

(14)

ARTICLE II, Section 2 (Number of Directors, Tenure and Qualifications) was revised by deleting that any director filling a vacancy as the result of an increase in the number of directors shall hold office until the next annual meeting but a decrease in the number of directors shall not shorten the term of an incumbent director, and that an election shall be held at an adjournment or a special meeting if not held at the annual meeting.

(15)	ARTICLE II, former Section 10 (Presumption of Assent) was deleted.

(16)	ARTICLE II, new Section 10 (Committees) was revised to delete certain restrictions with regards to committees.

(17)	ARTICLE II, Sections 11 (Action of the Board by Written Consent) and 12 (Conferences) were revised to provide for the possibility of electronic transmissions.

(18)	ARTICLE III, Section 6 (Chief Executive Officer, President) was revised to provide that unless another officer has been elected President of the Company, the Chief Executive Officer shall also be President and as such may, together with the Secretary, sign certificates for shares of the capital stock of the corporation.

(19)	ARTICLE III, Section 8 (Secretary and Assistant Secretaries) and ARTICLE IV, Section 1 (Shares of Stock) were revised to replace “Chief Executive Officer” with “President” as regards the signing of share certificates.

(20)	ARTICLE V, Section 1 (Indemnification Generally) was revised to delete employees and agents of the Company.

(21)	ARTICLE V, Section 4 (Determination that Indemnification is Proper) was revised to provide that present or former directors may demand that determination of entitlement to indemnification be made by independent counsel.

(22)	ARTICLE VI (Exclusive Form) was revised to include fiduciary duties owed by stockholders, actions in connection with the Company’s Certificate of Incorporation or By-laws, and all claims covered by the internal affairs doctrine.

---

---

(a)	Documents filed as part of this Report

1.	Financial Statements

2.	Financial Statement Schedule

3.	Exhibits

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

•	Services: Service revenue is generally recognized ratably over the contract term as the specified services are performed. Amounts received from customers in advance of rendering of services are classified as deferred income until the revenue can be recognized upon rendering of those services.

•	Extended Warranties: The Company offers its customers an option to purchase extended warranties on certain products. The Company recognizes revenue on these extended warranty contracts ratably over the life of the contract. The costs associated with these extended warranty contracts are recognized when incurred.

•

Multiple-Element Arrangements: Arrangements with customers may include multiple deliverables, including any combination of equipment, services and extended warranties. The deliverables included in the Company’s multiple-element arrangements are separated into more than one unit of accounting when (i) the delivered equipment has value to the customer on a stand-alone basis, and (ii) delivery of the undelivered service element(s) is probable and substantially in the control of the Company. Arrangement consideration is then allocated to each unit, delivered or undelivered, based on the relative selling price of each unit of accounting based first on vendor-specific objective evidence, if it exists, and then based on estimated selling price.

•

Vendor-specific objective: In most instances, products are sold separately in stand-alone arrangements. Services are also sold separately through renewals of contracts with varying periods. The Company determines vendor-specific objective based on its pricing and discounting practices for the specific product or service when sold separately, considering geographical, customer, and other economic or marketing variables, as well as renewal rates or stand-alone prices for the service element(s).

•

Estimated Selling Price: Represents the price at which the Company would sell a product or service if it were sold on a stand-alone basis. When vendor-specific objective evidence does not exist for all elements, the Company determines estimated selling price for the arrangement element based on sales, cost and margin analysis, as well as other inputs based on its pricing practices. Adjustments for other market and Company-specific factors are made as deemed necessary in determining estimated selling price.

---

---

---

---

---

---

---

---

---

---

---

---

---

(a)	Includes amounts recorded at Corporate headquarters and one distribution warehouse not managed by named segments.

(b)	Includes amounts recorded at Corporate headquarters.

---

(c)	Includes results of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

(d)	Includes capital expenditures of Corporate headquarters.

(e)	Includes assets of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

(a)	This category includes fixed income securities invested primarily in Swiss bonds, foreign bonds denominated in Swiss francs, foreign currency bonds, mortgage notes and pledged letters.

(b)	This category includes mutual funds balanced between moderate-income generation and moderate capital appreciation with investment allocations of approximately 50% equities and 50% fixed income investments.

(c)	This category includes common/collective funds with investments in approximately 65% equities and 35% in fixed income investments.

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

ARTICLE I STOCKHOLDERS’ MEETINGS..................................................................................	1

Section 1.	Annual Meetings...........................................................................................1

Section 2.	Special Meetings...........................................................................................    1

Section 3.	Place of Meeting...........................................................................................    1

Section 4.	Notice of Meeting.........................................................................................    1

Section 5.	Fixing of Record Date..................................................................................    2

Section 6.	Quorum; Adjournments..............................................................................    2

Section 7.	Proxies...........................................................................................................    3

Section 8.	Voting of Shares...........................................................................................    3

Section 9.	List of Stockholders.....................................................................................    3

Section 10.	Waiver of Notice by Stockholders..............................................................    4

Section 11.	Advance Notice of Stockholder-Proposed Business at Annual Meetings........................................................................................................    4

Section 12.	Procedure for Nomination of Directors.....................................................    6

Section 12a.	Stockholder Nominations Included in the Corporation’s Proxy Statement......................................................................................................    7

Section 13.	Stockholder Voting.....................................................................................16

Section 14.	Conduct of Meetings..................................................................................17

---

Section 1.	General Powers................................................................................    17

Section 2.	Number of Directors, Tenure and Qualifications..........................    18

Section 3.	Regular Meetings.............................................................................    18

Section 4.	Special Meetings...............................................................................    18

Section 5.	Notice.................................................................................................18

Section 6.	Quorum.............................................................................................    19

Section 7.	Manner of Acting.............................................................................    19

Section 8.	Vacancies...........................................................................................    19

Section 9.	Compensation...................................................................................    19

Section 10.	Committees.......................................................................................    19

Section 11.	Action of the Board by Written Consent.......................................    20

Section 12.	Conferences......................................................................................    20

ARTICLE III OFFICERS......................................................................................................	20

Section 1.	Number..............................................................................................    20

Section 2.	Election and Term of Office............................................................    20

Section 3.	Removal............................................................................................    20

Section 4.	Executive Chairman of the Board..................................................    21

Section 5.	Lead Independent Directors...........................................................    21

Section 6.	Chief Executive Officer; President.................................................    21

Section 7.	Senior Vice President and Vice Presidents....................................    21

Section 8.	Secretary and Assistant Secretaries................................................    21

Section 9.	Treasurer and Assistant Treasurer.................................................    22

Section 10.	Salaries..............................................................................................    22

Section 11.	Representation in Other Companies..............................................    22

---

ARTICLE IV STOCK AND TRANSFER OF STOCK.........................................................	22

Section 1.	Shares of Stock.................................................................................    22

Section 2.	Transfer of Shares............................................................................    23

ARTICLE V INDEMNIFICATION OF DIRECTORS, OFFICERS,....................................	23

Section 1.	Indemnification Generally..............................................................    24

Section 2.	Indemnification in Actions By or In the Right Of the Corporation......................................................................................    24

Section 3.	Success on the Merits; Indemnification Against Expenses..........    24

Section 4.	Determination that Indemnification is Proper..............................    25

Section 5.	Insurance; Indemnification Agreements........................................    25

Section 6.	Advancement of Expenses...............................................................    25

Section 7.	Rights Not Exclusive........................................................................    26

Section 8.	Severability.......................................................................................    26

Section 9.	Modification......................................................................................    26

ARTICLE VI EXCLUSIVE FORUM...................................................................................	26

ARTICLE VII CERTAIN GOVERNANCE MATTERS.......................................................	27

Section 1.	Definitions.........................................................................................    27

Section 2.	Composition of the Board...............................................................    27

Section 3.	Chairman, Chief Executive Officer, Lead Independent Director..............................................................................................    28

Section 4.	Required Committees......................................................................    28

Section 5.	Amendments.....................................................................................    28

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

ARTICLE I

---

---

---

ARTICLE IV

---

---

ARTICLE VII

---

ARTICLE X

---

---

---

ARTICLE XIII

ARTICLE XVI

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

A.	It is the desire of the Company to assure itself of the services of Executive effective as of February 29, 2016 (the “Effective Date”) and thereafter by entering into this Agreement.

B.	Executive and the Company mutually desire that Executive provide services to the Company on the terms herein provided.

1.	Employment.

2.	Compensation and Related Matters.

3.	Termination.

4.	Severance Payments.

5.

Covenants. Executive acknowledges that Executive has been provided with Confidential Information (as defined below) and, during the Term, the Company from time to time will provide Executive with access to Confidential Information. Ancillary to the rights provided to Executive as set forth in this Agreement and the Company’s provision of Confidential Information, and Executive’s agreements regarding the use of same, in order to protect the value of any Confidential Information, the Company and Executive agree to the following provisions, for which Executive agrees he received adequate consideration and which Executive acknowledges are reasonable and necessary to protect the legitimate interests of the Company and represent a fair balance of the Company’s rights to protect its business and Executive’s right to pursue employment:

6.	Nondisclosure of Proprietary Information.

7.	Inventions.

8.	Injunctive Relief.

9.

Maximum Payment Limit. If any payment or benefit due under this Agreement, together with all other payments and benefits that Executive receives or is entitled to receive from the Company or any of its subsidiaries, Affiliates or related entities, would (if paid or provided) constitute an excess parachute payment for purposes of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), the amounts otherwise payable and benefits otherwise due under this Agreement will either (i) be delivered in full, or (ii) be limited to the minimum extent necessary to ensure that no portion thereof will fail to be tax-deductible to the Company by reason of Section 280G of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state or local income and employment taxes and the excise tax imposed under Section 4999 of the Code, results in the receipt by the Executive, on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be subject to the excise tax imposed under Section 4999 of the Code. In the event that the payments and/or benefits are to be reduced pursuant to this Section 9, such payments and benefits shall be reduced such that the reduction of cash compensation to be provided to the Executive as a result of this Section 9 is minimized. In applying this principle, the reduction shall be made in a manner consistent with the requirements of Section 409A of the Code and where two economically equivalent amounts are subject to reduction but payable at different times, such amounts shall be reduced on a pro rata basis but not below zero. All determinations required to be made under this Section 9 shall be made by the Company’s independent public accounting firm, or by another advisor mutually agreed to by the parties, which shall provide detailed supporting calculations both to the Company and Executive within fifteen (15) business days of the receipt of notice from Executive that there has been a payment or benefit subject to this Section 9, or such earlier time as is requested by the Company.

10.	Clawback Provisions.

11.	Assignment and Successors.

12.	Certain Definitions.

13.	Miscellaneous Provisions.

(i)	If to the Company, to the attention of the General Counsel at its headquarters,

14.	Executive Acknowledgement.

A.	It is the desire of the Company to assure itself of the services of Executive effective as of the Effective Date and thereafter by entering into this Agreement.

B.	Executive and the Company mutually desire that Executive provide services to the Company on the terms herein provided.

1.	Employment.

2.	Compensation and Related Matters.

3.	Termination.

4.	Severance Payments.

5.	Covenants.

6.	Nondisclosure of Proprietary Information.

7.	Inventions.

8.	Injunctive Relief.

9.	Maximum Payment Limit.

10.	Clawback Provisions.

11.	Assignment and Successors.

12.	Certain Definitions.

13.	Miscellaneous Provisions.

(i)	If to the Company, to the attention of the General Counsel at its headquarters,

14.	Executive Acknowledgement.

A.	It is the desire of the Company to assure itself of the services of Executive effective as of the Effective Date and thereafter by entering into this Agreement.

B.	Executive and the Company mutually desire that Executive provide services to the Company on the terms herein provided.

---

---

---

---

---

---

---

---

---

---

---

---

---

1.	Advanced Technology Research SRL (Italy)

2.	Arges Imaging, Inc. (Delaware)

3.	CCRI, Inc. (Delaware)

4.	Ceramco Manufacturing B.V. (Netherlands)

5.	D Luxembourg Sarl (Luxembourg)

6.	DeguDent GmbH (Germany)

7.	Dencril Comércio de Plásticos, Importação e Exportação Ltda. (Brazil)

8.	Dental Implant Training Center Corp. (New Jersey)

9.	Dentbras Indústria, Comércio, Importação e Exportação de Produtos Odontológicos Ltda. (Brazil)

10.	Dentsply (Australia) Pty. Ltd. (Australia)

11.	Dentsply (N.Z.) Limited (New Zealand)

12.	Dentsply (Philippines) Inc. (Philippines)

13.	Dentsply (Singapore) Pte. Ltd. (Singapore)

14.	Dentsply (Thailand) Ltd. (Thailand)

15.	Dentsply (Tianjin) International Trading Co. Ltd. (China)

16.	Dentsply Acquisition S.a.r.l. (Luxembourg)

17.	Dentsply Acquisition US LLC (Delaware)

18.	Dentsply Argentina S.A.C.e.I. (Argentina)

19.	Dentsply Asset Management GmbH & Co. KG (Germany)

20.	Dentsply AT Sarl (Luxembourg)

21.	Dentsply Benelux B.V. (Netherlands)

22.	Dentsply Benelux Sarl (Luxembourg)

23.	Dentsply BI Ltd. (Ireland)

24.	Dentsply BX Sarl (Luxembourg)

25.	Dentsply Canada Ltd. (Canada)

26.	Dentsply CE S.a.r.l. (Luxembourg)

27.	Dentsply CH Sarl (Luxembourg)

28.	Dentsply Dental (Tianjin) Co. Ltd. (China)

29.	Dentsply Dental GmbH (Germany)

30.	Dentsply Dental S.a.r.l. (Luxembourg)

31.	Dentsply DeTrey GmbH (Germany)

32.	Dentsply DeTrey Sarl (Switzerland)

33.	Dentsply Deutschland GmbH (Germany)

34.	Dentsply Europe S.a.r.l. (Luxembourg)

35.	DENTSPLY Finance Co. (Delaware)

36.	Dentsply GAC Europe SAS (France)

37.	Dentsply Germany GmbH (Germany)

38.	Dentsply Germany Holdings GmbH (Germany)

39.	Dentsply Germany Investments GmbH (Germany)

40.	Dentsply Holdings S.a.r.l. (Luxembourg)

41.	Dentsply Holdings Unlimited (U.K.)

42.	Dentsply Iberia S.A. (Spain)

43.	Dentsply IE Ltd. (Ireland)

44.	Dentsply IH A/S (Denmark)

45.	Dentsply IH AB (Sweden)

---

46.	Dentsply IH AS (Norway)

47.	Dentsply IH GmbH (Austria)

48.	Dentsply IH GmbH (Germany)

49.	Dentsply IH Holdings GmbH (Germany)

50.	Dentsply IH Inc. (Delaware)

51.	Dentsply IH LLC(Russia)

52.	Dentsply IH Ltd (UK)

53.	Dentsply IH Oy (Finland)

54.	Dentsply IH Pty. Ltd. (Australia)

55.	Dentsply IH S.A. (Switzerland)

56.	Dentsply IH SP.z.o.o (Poland)

57.	DENTSPLY Implants (China) Co. Limited (Hong Kong)

58.	DENTSPLY Implants (HK) Co. Limited (Hong Kong)

59.	Dentsply Implants Manufacturing GmbH (Germany)

60.	Dentsply Implants NV (Belgium)

61.	Dentsply Implants Taiwan Co, Ltd. (Taiwan)

62.	Dentsply Implants Turkey (Turkey)

63.	Dentsply India Pvt. Ltd. (India)

64.	Dentsply Industria e Comercio Ltda. (Brazil)

65.	Dentsply Israel Ltd. (Israel)

66.	Dentsply Italia SrL (Italy)

67.	Dentsply Korea Limited (Korea)

68.	Dentsply Limited (Cayman Islands)

69.	Dentsply LLC (Delaware)

70.	Dentsply Mexico S.A. de C.V. (Mexico)

71.	DENTSPLY North America LLC (Delaware)

72.	Dentsply Peru SAC (Peru)

73.	Dentsply Prosthetics Austria GmbH (Austria)

74.	DENTSPLY Prosthetics U.S. LLC (Delaware)

75.	Dentsply RU Limited Liability Company (Russia)

76.	Dentsply Russia Limited (U.K.)

77.	Dentsply Sarl (Luxembourg)

78.	Dentsply SE Sarl (Luxembourg)

79.	Dentsply Services (Switzerland) S.a.r.L. (Switzerland)

80.	Dentsply Sirona France S.A.S. (France)

81.	Dentsply Sirona Malaysia Sdn Bhd (Malaysia)

82.	Dentsply Sirona Switzerland Sarl (Switzerland)

83.	Dentsply Sirona Vietnam Company Limited (Vietnam)

84.	Dentsply Sirona South Africa (Proprietary) Limited (South Africa)

85.	Dentsply Sweden AB (Sweden)

86.	Dentsply Ukraine LLC (Ukraine)

87.	Dentsply US Inc. (Delaware)

88.	DENTSPLY-Sankin K.K. (Japan)

89.	Ducera Dental Verwaltungs GmbH (Germany)

90.	Durango Bensheim GmbH & Co. KG (Germany)

91.	Durango Bensheim Verwaltungs GmbH (Germany)

92.	E.S. Healthcare NV (Belgium)

93.	E.S. Tooling NV (Belgium)

94.	FONA Dental s.r.o. (Slovakia)

95.	FONA Dental Systems Co., Ltd. (China)

96.	FONA s.r.l. (Italy)

---

97.	Futuredontics, Inc. (California)

98.	GAC (International) Pty Ltd (Australia)

99.	GAC Deutschland GmbH (Germany)

100.	GAC International Asia Pte. Ltd. (Singapore)

101.	GAC International LLC (Delaware)

102.	GAC Ortho AS (Norway)

103.	GAC SA (Switzerland)

104.	infiniDent Services GmbH (Germany)

105.	Infinident, Inc. (Delaware)

106.	JCM International Inc. (Delaware)

107.	M Guide Dental Laboratory LLC (New Jersey)

108.	Maillefer Instruments Consulting S.a.r.l. (Switzerland)

109.	Maillefer Instruments Holding S.a.r.l. (Switzerland)

110.	Maillefer Instruments Manufacturing S.a.r.l. (Switzerland)

111.	Maillefer Instruments Plus Sarl (Switzerland)

112.	Maillefer Instruments Trading S.a.r.l. (Switzerland)

113.	Medical 3 Importacion Service Iberica SL (Spain)

114.	Megalopolis Dental S.A. de C.V. (Mexico)

115.	MHT Optic Research AG (Switzerland)

116.	MHT S.p.A. (Italy)

117.	MIS Asia Pacific Limited (Hong Kong)

118.	MIS Belgium SA (Belgium)

119.	MIS Germany GmbH (Germany)

120.	MIS Implants B.V. (Netherlands)

121.	MIS Implants Technologies France SRL (France)

122.	MIS Implants Technologies GmbH (Germany)

123.	MIS Implants Technologies HK Limited (Hong Kong)

124.	M.I.S. Implants Technologies Inc. (New Jersey)

125.	MIS Implants Technologies Ltd. (Israel)

126.	MIS Implants Technologies UK Limited (UK)

127.	Nectar Imaging s.r.l. (Italy)

128.	Oasis Dis Ticaret Anonim Sirketi (Turkey)

129.	Oasis Medikal Urunler Kimya Turizm Sanayi Ve Ticaret Anonim Sirketi (Turkey)

130.	Ortho Concept Sarl (France)

131.	Orthodental International, Inc. (California)

132.	Orthodental S.A. de C.V. (Mexico)

133.	Osteointegration Materials LLC (Delaware)

134.	Planer Dentaprise GmbH (Austria)

135.	Prident (Shanghai) Dental Medical Devices Co., Ltd. (China)

136.	Prident International, Inc. (California)

137.	PT Dedent Supply (Indonesia)

138.	PT Dentsply Indonesia (Indonesia)

139.	Qi An Hua Rui (Beijing) Technology Ltd. (China)

140.	Raintree Essix Inc. (Delaware)

141.	Ransom & Randolph Company (Delaware)

142.	Shenzen Mi Yi Shi Commerce Company Ltd (China)

143.	SiCAT GmbH & Co. KG (Germany)

144.	SiCAT Verwaltungs GmbH (Germany)

145.	Sirona Bermuda I Ltd. (Bermuda)

146.	Sirona Bermuda II Ltd. (Bermuda)

147.	Sirona Dental a/s (Denmark)

---

148.	Sirona Dental Comércio de Produtos e Sistemas Odontológicos Ltda. (Brazil)

149.	Sirona Dental GmbH (Austria)

150.	Sirona Dental Limited Sirketi (Turkey)

151.	Sirona Dental Mexico S. de R.L. de C.V. (Mexico)

152.	Sirona Dental Services GmbH (Germany)

153.	Sirona Dental Systems (Foshan) Co., Ltd. (China)

154.	Sirona Dental Systems (HK) Ltd. (Hong Kong)

155.	Sirona Dental Systems Co., Ltd (Thailand)

156.	Sirona Dental Systems GmbH (Germany)

157.	Sirona Dental Systems Inc. (Delaware)

158.	Sirona Dental Systems K.K. (Japan)

159.	Sirona Dental Systems Korea, Ltd. (South Korea)

160.	Sirona Dental Systems Ltd. (United Kingdom)

161.	Sirona Dental Systems O.O.O. (Russia)

162.	Sirona Dental Systems Private Ltd. (India)

163.	Sirona Dental Systems Pte. Ltd (Singapore)

164.	Sirona Dental Systems Pty. Ltd. (Australia)

165.	Sirona Dental Systems s.r.l. (Italy)

166.	Sirona Dental Systems SAS (France)

167.	Sirona Dental Systems South Africa (Pty) Ltd. (South Africa)

168.	Sirona Dental Systems Trading (Shanghai) Co., Ltd. (China)

169.	Sirona Dental Systems Trading, LLC (United Arab Emirates)

170.	Sirona Dental, Inc. (Delaware)

171.	Sirona Holding GmbH (Austria)

172.	Sirona Immobilien GmbH (Germany)

173.	Sirona Technologie GmbH & Co. KG (Germany)

174.	Sirona Verwaltungs GmbH (Germany)

175.	The Dental Trading Co., Ltd. (Thailand)

176.	Tulsa Dental Products LLC (Delaware)

177.	Tulsa Luxembourg LLC (Delaware)

178.	Tuzodent S.A. de C.V. (Mexico)

179.	VDW GmbH (Germany)

180.	VIPI Indústria, Comércio, Exportação e Importação de Produtos Odontológicos Ltda. (Brazil)

181.	VPN Administração e Participações S.A. (Brazil)

182.	Zhermack GmbH (Germany)

183.	Zhermack SpA (Italy)

184.	Zhermack, Inc. (Nevada)

185.	Zhermapol SP Zoo (Poland)

1.	I have reviewed this Form 10-K of DENTSPLY SIRONA Inc;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

1.	I have reviewed this Form 10-K of DENTSPLY SIRONA Inc;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.